Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects-Reference-Cited by-同舟云学术

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Published:2023-04-29 Issue:6 Volume:102 Page:1395-1408
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Geelen Inge G.P.^ORCID,Gullaksen Stein-Erik,Ilander Mette M.,Olssen-Strömberg Ulla,Mustjoki Satu,Richter Johan,Blijlevens Nicole M.A.,Smit Willem M.,Gjertsen Bjorn T.,Gedde-Dahl Tobias,Markevärn Berit,Koppes Malika M.A.,Westerweel Peter E.,Hjorth-Hansen Henrik,Janssen Jeroen J.W.M.

Funder

Novartis Pharma

MSD France

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05199-1.pdf

Reference56 articles.

1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34:2851–2857. https://doi.org/10.1200/JCO.2015.66.2866

2. Hehlmann R, Lauseker M, Saussele S et al (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31:2398–2406. https://doi.org/10.1038/leu.2017.253